Floatz logo

Tislelizumab

Hodgkin Lymphoma

Xiuhua Sunmonoclonal_antibodyPhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
65/ 100

Competitive context

149 Active assets in the Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB

View all 50 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →